2a
General Information
DCTPep ID DCTPep05997
Peptide Name 2a
Sequence CFETLRGEERILSILRHQNLLKELQD
Sequence Length 26
UniProt ID Not available
PubChem CID Not available
Origin Synthetic (Derived from chromogranin A)
Type Synthetic peptide
Classification
Cancer targeted peptides αvβ6/αvβ8 inhibitor
Activity Information
Hemolytic Activity Not available
Normal (non-cancerous) Cytotoxicity Not available
Target αvβ6, αvβ8
Affinity αvβ6: Ki>50000 nM; αvβ8: Ki>50000 nM
Mechanism Not available
Structure Information
PDB ID Not available
Predicted Structure Not available
(Please note that there is the predicted structure, predicted by AlphaFold)
Helicity Not available
Linear/Cyclic Linear
Disulfide/Other Bond Not available
N-terminal Modification Free
C-terminal Modification Amidation
Other Modification None
Chiral L
Physicochemical Information
Formula C137H229N41O42S1
Absent amino acids AMPVWY
Theoretical pI 5.59
Acidic residues 5
Basic residues 5
Polar residues 5
Molecular weight (Average) 3154.63
Molecular weight (Monoisotopic) 3152.68
Common amino acids L
Net charge 0
Instability index (II) 69.71
Aliphatic index 120.00
Grand average of hydropathicity (GRAVY) -0.515
Half Life
1.2 hours (mammalian reticulocytes, in vitro).
>20 hours (yeast, in vivo).
>10 hours (Escherichia coli, in vivo).
Extinction coefficients
Ext. coefficient 0
Abs 0.1% (=1 g/l) 0.000, assuming all pairs of Cys residues form cystines
Ext. coefficient 0
Abs 0.1% (=1 g/l) 0.000, assuming all Cys residues are reduced
Amino acid distribution
Literature Information
Literature 1
Pubmed ID 36594095
Title A stapled chromogranin A-derived peptide homes in on tumors that express αvβ6 or αvβ8 integrins
Year 2023
Patent
Patent ID Not available
Patent Title Not available
Other Iinformation Not available
Other Published ID Not available